Kirk Campbell, MD

Dr. Kirk Campbell is the Irene and Dr. Arthur M. Fishberg Professor of Medicine and Professor of Pharmacological Sciences and inaugural Director of the Mount Sinai Center for Kidney Disease Innovation. The Center integrates multidisciplinary glomerular disease, polycystic kidney disease, onco-nephrology and diabetic kidney disease (DKD) clinical programs into a translational research framework. The goal is to leverage state-of-the-art genomic, bioinformatics and molecular phenotyping technology to identify novel therapeutic targets for drug discovery and biomarker validation while expanding patient registry, biobanking, and clinical trial opportunities. These efforts enhance early detection, prevention, and treatment of kidney disease and its complications while expanding Mount Sinai's precision medicine capabilities.

Dr. Campbell received his medical degree from the University of Connecticut. He completed his internal medicine residency at Yale University before pursuing clinical nephrology and postdoctoral research training at Mount Sinai. Dr. Campbell is the President-elect of the National Kidney Foundation, former President of the New York Society of Nephrology, and a member of the Board of Directors of the Nephcure Foundation. He is the recipient of a Distinguished Leader Award from the American Society of Nephrology ,and an elected member of the American Society for Clinical Investigation. Additionally, Dr. Campbell is an active member of the editorial boards of American Journal of Kidney Disease, Kidney360, Kidney International, Frontiers in Medicine and the American Journal of Physiology – Renal Physiology.

Dr. Campbell is the principal investigator (PI) of Mount Sinai’s Kidney Precision Project Recruitment Site, an NIH-funded initiative to identify new markers and treatment targets for personalized, effective, and safe treatments for kidney diseases. He has been awarded a Harrington Discovery Institute Scholar Innovator grant to advance the development of a promising therapeutic intervention for proteinuric kidney disease.